JAPAN’S second biggest
pharmaceutical company, Astellas
Pharma, has signed a US$4 billion
deal to purchase US company OSI
Pharmaceuticals.
OSI makes blockbuster cancer
drug Tarceva, and Astellas is
hoping to boost its presence in the
US market where it recently lost
patent protection for its urinary
medication Flomax and transplant
drug Prograf.The above article was sent to subscribers in Pharmacy Daily's issue from 18 May 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 May 10
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.